The Partnership to Improve Patient Care, a coalition that represents the drug, medical-device and biotech sectors, is seeking to remove a provision in the U.S. House's version of the stimulus bill that would allot $1.1 billion for comparative-effectiveness studies. Such research might be used "in an inappropriate manner that may limit treatment options for patients," said David Di Martino, a spokesman for the coalition.

Related Summaries